The biotech’s efforts to bring its vaccines to the country mean navigating political pushback in the U.S. and the risk of ...
In absolute dollar amount, the Cambridge drugmaker had the biggest drop in market cap among any public Massachusetts company ...
The Covid-19 positivity rate has also seen a rise to 7.1% this past week, versus the 5.5% figure for the past four weeks.
Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.
Despite millions of cases of norovirus in the U.S. each year—and a current surge in outbreaks—there is still no vaccine for ...
With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...
Moderna shares soared as investors placed bets that the pharmaceutical giant’s development of an H5N1 bird flu vaccine could ...
Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.
Moderna (MRNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Shares of Moderna Inc. fell over 8% on Wednesday afternoon, paring some of the gains from Tuesday, the stock’s best trading ...